The monkeypox epidemic is spreading rapidly and is already a global health emergency. The last weekend of July, Spain has recorded two deaths from monkeypox. Both cases have been reported to the World Health Organization and the European Commission. To date, a total of 4,298 cases of monkeypox have been reported in the country, according to data from the National Epidemiological Surveillance Network (Renave).
The first monkeypox death occurred in the Valencian Community due to encephalitis associated with the infection in a man. The second took place in Andalusia. He is a 31-year-old man who remained in the intensive care unit of the Reina Sofía University Hospital in Cordoba. In this case, the cause of death was meningoencephalitis, although the autopsy is still in progress to determine if it was indeed this disease or another pathology.
The Ministry of Health has indicated, like the rest of the countries, that cases have been identified in particular in the MSM populationthat is, men who have sex with other men, the mechanism of transmission being in the vast majority of cases very close physical contact, mainly in the context of high-risk sexual relations.
On the other hand, the department of the Minister of Health, Carolina Darias, pointed out that if said “transmission is not optimally controlled, there will be a significant risk that other population groups will be displaced by the same transmission mechanism, with the possibility of affecting other groups and the appearance of serious cases in the most vulnerable population”.
The The Danish pharmaceutical company Bavarian Nordic received approval of the European Commission to market its vaccine against monkeypox (Imvanex). The previous week, the European Medicines Agency (EMA) approval recommended.
The dose had already obtained approval for the prevention of pathology in the United States and Canada, where it is marketed as Jynneos. Moreover, prior to the EMA approval, the pharmaceutical company had already supplied serums to several countries in the European Union.
Imvanex It was approved in Europe in 2013 for smallpox vaccination in adults over 18 years of age. The committee is now advising Europe to accept the vaccine as a treatment for monkeypox at a time when infections are rising in some countries. In the United States and Canada, the authorization of Imvanex has been extended to include the virus among the indications.
In May, when the cases of monkeypox appeared in Spain, the Minister of Health announced that Europe would buy antivirals for this disease from the Danish pharmaceutical company through a centralized purchase in which Spain would participate.